Hypothalamic ghrelin signalling mediates olanzapine-induced hyperphagia and weight gain in female rats

52Citations
Citations of this article
39Readers
Mendeley users who have this article in their library.

Abstract

Abstract Excessive weight gain is a major metabolic side effect of second-generation antipsychotics (SGAs) in the treatment of schizophrenia. Ghrelin is an orexigenic hormone secreted mainly from the stomach, which can induce weight gain and hyperphagia through regulating neuropeptides at the hypothalamus. Accumulating evidence implicates a relationship between ghrelin signalling and SGA-induced hyperphagia and weight gain. We report that olanzapine (a SGA with high weight gain liability) potently and time-dependently up-regulate ghrelin and ghrelin signalling, leading to hyperphagia and weight gain in female Sprague-Dawley rats, an action reversed by i.c.v. injection of a ghrelin receptor (GHS-R1a) antagonist. These findings indicate a crucial role of ghrelin signalling in hyperphagia induced by olanzapine, supporting the notion that GHS-R1a antagonist may be useful for pharmacological treatment of SGA-induced weight gain resulted from hyperphagia. © CINP 2014.

Cite

CITATION STYLE

APA

Zhang, Q., He, M., Deng, C., Wang, H., Lian, J., & Huang, X. F. (2014). Hypothalamic ghrelin signalling mediates olanzapine-induced hyperphagia and weight gain in female rats. International Journal of Neuropsychopharmacology, 17(5), 807–818. https://doi.org/10.1017/S1461145713001697

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free